Navigation Links
Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
Date:11/5/2009

hich may result in the discontinuation or delay of the research or development projects; the risk of technical obsolescence; the need for further regulatory approvals, which may not be obtained in a timely matter or at all; intellectual property risks, including without limitation, the risk that three patents for Topical Interferon Alpha-2b will expire in 2013 and no additional patent may be issued, that patent applications may not result in issued patents, that issued patents may be circumvented or struck down, and the risk of potential claims of infringement by the Company of third party intellectual property rights; marketing/manufacturing and partnership/strategic alliance risks; the effect of competition; uncertainty of the size and existence of a market opportunity for Helix's product; the risk that the Company's supplier of interferon alpha-2b may not continue to provide the Company with interferon alpha-2b or exercise its commercialization option, which would have a negative effect on the further development of the drug candidate and on the Company; and the risk of changes in business strategy or development plans. Certain of these risks and uncertainties, and others affecting the Company which could cause actual results to vary materially from current results or those anticipated in forward-looking statements and information, are more fully described in the Company's latest MD&A, Form20-F and other reports filed with the Canadian Securities Regulatory Authorities and the U.S. SEC from time to time at www.sedar.com and www.sec.gov/edgar.shtml, respectively. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations change, except as required by law.


'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Helix BioPharma Corp. Announces Fiscal 2009 Results
2. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
3. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
4. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
5. PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction
6. Lilly CEO Lechleiter Calls for Repair of the Engine of Biopharma Innovation
7. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
8. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
9. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
10. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
11. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015  Abaxis, Inc. (NasdaqGS: ABAX ), a ... today that Ross Taylor , vice president of ... of chief financial officer effective August 1, 2015, will ... Thursday, June 4, 2015 at 10:00 a.m. ET. The ... New York City . ...
(Date:5/27/2015)... DUBLIN, Ohio , May 27, 2015 /PRNewswire/ ... present a new series of health economic outcomes ... evaluating real-world treatment patterns when developing value-based reimbursement ... , vice president and chief medical officer of ... and pharmaceutical companies alike have known for more ...
(Date:5/27/2015)... , May 27, 2015  Relmada Therapeutics, Inc. ... the treatment of chronic pain, announced today that it ... on Monday, June 1, 2015 at the Luxe Sunset ... The presentation by Michael Becker ... development, is scheduled to begin at 2:00 p.m. PT/5:00 ...
Breaking Medicine Technology:New Studies Reinforce Important Role Real-World Patient Data Can Play in Developing Value-based Reimbursement Strategies 2New Studies Reinforce Important Role Real-World Patient Data Can Play in Developing Value-based Reimbursement Strategies 3Relmada Therapeutics to Present at the 2015 LD Micro Invitational Conference 2Relmada Therapeutics to Present at the 2015 LD Micro Invitational Conference 3
... Feb. 27, 2012  Ventana Medical Systems, Inc. (Ventana), a member ... U.S. Food and Drug Administration (FDA) for the VENTANA ... the VENTANA iScan Coreo Au scanner running ... company offering an FDA cleared Ki-67 image analysis algorithm ...
... Feb. 27, 2012 Accuray Incorporated (Nasdaq: ARAY ... president and chief executive officer, Euan S. Thomson, Ph.D., is ... in Boston on Tuesday, March 6, 2012 at 8:00 a.m. ... presentations will be available online from the Investor Relations page ...
Cached Medicine Technology:Ventana Receives FDA Clearance for Ki-67 (30-9) Image Analysis and Digital Read Applications 2Accuray Incorporated's CEO to Speak at Cowen and Company 32nd Annual Healthcare Conference 2
(Date:5/27/2015)... Jose, CA (PRWEB) May 27, 2015 Splashtop ... its latest addition to its screen mirroring and extended display ... Whether in a conference room, classroom, or family room, users ... a large TV / display connecting to an Apple TV, ... Amazon Fire TV, Amazon Fire TV Stick, or the Google ...
(Date:5/27/2015)... CRN International, the radio marketing and promotions ... Financial Officer. , Prinner most recently was Principal of ... financial/operational executive positions at telecom and technology services companies ... and SNET. His accounting and consulting career began ... will be able to tap into his experience of ...
(Date:5/27/2015)... Louisville, KY (PRWEB) May 27, 2015 ... or worse because of lack of compliance documentation or ... a recycler in Miami, a propane gas company in ... doling out fines for incidents and accidents due to ... System (LMS) is proud to introduce the new ...
(Date:5/27/2015)... TX (PRWEB) May 27, 2015 Congratulations ... The Torch” Addiction Treatment Scholarship Award. From June 1, ... $10,000 to 50 drug and alcohol addiction treatment centers ... treatment. Scholarships were drawn at random at addiction treatment ... for Sky Toxicology, Matt Green said, “Sky Toxicology would ...
(Date:5/27/2015)... 2015 Altec Products, Inc., a leader ... their Premier Sponsorship of Connections 2015. The all-day client ... Thursday, May 28th and will deliver to clients both ... the roadmap to get there. , Arxis Technology, ... sale, installation and support of Intacct Cloud Financials, Adaptive ...
Breaking Medicine News(10 mins):Health News:Splashtop Launches the Fastest Computer Screen Mirroring and Extended Display Solution – to Apple TV and other Smart Displays 2Health News:Splashtop Launches the Fastest Computer Screen Mirroring and Extended Display Solution – to Apple TV and other Smart Displays 3Health News:CRN International Names New Chief Financial Officer 2Health News:New Supervisor Feature Streamlines HR Compliance Reporting and Documentation 2Health News:New Supervisor Feature Streamlines HR Compliance Reporting and Documentation 3Health News:Sky Toxicology Reaches Their $500,000 Goal in Drug and Alcohol Addiction Treatment Patient Scholarship Awards 2Health News:Sky Toxicology Reaches Their $500,000 Goal in Drug and Alcohol Addiction Treatment Patient Scholarship Awards 3Health News:Altec Sponsors Connections 2015, Arxis Technology, Inc.’s Client Conference, Bringing Valuable Document Management Solution to Attendees 2Health News:Altec Sponsors Connections 2015, Arxis Technology, Inc.’s Client Conference, Bringing Valuable Document Management Solution to Attendees 3
... OUT TO EDUCATE CHICAGOANS, CHICAGO, Jan. 25 ... of Chicago, SAVE THE PATIENT, a,not-for-profit patient-focused organization, is ... Access Network (CAN-TV) and,will air on Monday, January 28, ... will feature a frank discussion on how to make ...
... study finds , , FRIDAY, Jan. 25 (HealthDay News) ... States hit $174 billion in 2007, a 32 percent ... research, commissioned by the American Diabetes Association (ADA), found ... $116 billion, and a disproportionate percentage of those costs ...
... Time with,Friends and Family, SACRAMENTO, Calif., Jan. 25 ... senior citizen center to enjoy the company,of other seniors. ... for her to go to the dining room, and ... donated by The SCOOTER Store,Mrs. Pittman can now enjoy ...
... needed to confirm the findings, experts say , , FRIDAY, Jan. ... lutein could lower a woman,s risk of sight-robbing cataracts, new ... 35,000 women aged 45 and older. , "The data suggests ... total vitamin E may have a lower risks of cataracts," ...
... Inc. (NYSE:,WLP) announced today that senior management is ... January 30, 2008. The presentation is,expected to begin ... interested parties are invited to listen to the ... and selecting the "Investor,Info" link. Following the presentation, ...
... WARSAW, Ind., Jan. 25 Symmetry Medical Inc.,(NYSE: ... to the global orthopaedic,device industry and other medical ... announced acquisition of DePuy Orthopaedics, Inc,s,facility for orthopaedic ... in cash., As originally announced in December ...
Cached Medicine News:Health News:Making the Most Out of Your Doctor's Visit 2Health News:Diabetes' Health Toll Hits $174 Billion Annually 2Health News:Disabled Sacramento Woman, 110, Receives Power Wheelchair Donation from The SCOOTER Store 2Health News:Vitamin E, Lutein May Fight Cataracts 2Health News:Vitamin E, Lutein May Fight Cataracts 3Health News:WellPoint Announces Appearance at Upcoming Conference 2Health News:Symmetry Medical Completes Acquisition of DePuy Orthopaedic Instrument Facility 2
... for catheter or instrument introduction. The ... be peeled away and removed. The ... instrument to be introduced should be ... the sheath. Supplied sterile in peel-open ...
Used to gain percutaneous access into the renal pelvis to treat stone disease. The dual lumen catheter and the Peel-Away® introducer are sized for use in pediatric patients. Supplied sterile in p...
Supplied sterile in peel-open packages. Intended for one-time use....
Used when establishing a percutaneous tract for nephrostomy drainage. The wire guide has an extra stiff shaft and a gradual transition to a very flexible tip. Supplied sterile in peel-open packages. ...
Medicine Products: